Literature DB >> 3122216

Molecular basis of the cell-surface expression of immunoglobulin mu chain without light chain in human B lymphocytes.

B A Pollok1, R Anker, P Eldridge, L Hendershot, D Levitt.   

Abstract

Four distinct human B-lymphoid cell lines possess the ability to circumvent the mechanism regulating intracellular transport of immunoglobulin protein. These cells do not produce light chains, yet they express mu heavy chains on the cell surface at comparable levels to B-cell lines that produce native forms of both proteins. The mu-chain mRNA produced in all four cell lines was found to contain an identical deletion of most of the heavy-chain variable (VH) region (75% of the 3' portion), with no apparent alteration in constant (C) region structure. The truncated mu (mu*)-chain mRNA in these cells was created through the use of a cryptic splice donor site found within the human VH gene(s) utilized by these B-cell lines. The truncated mu chains exhibited a decreased ability to associate with the intracellular transport regulatory protein, heavy-chain binding protein (BiP). This result indicates that VH region structure, in addition to C mu 1 region structure, influences the formation of the BiP recognition site on the heavy chain. Furthermore, it suggests that the mechanism allowing for cell-surface expression of the mu* chains in the absence of light-chain pairing is the inability of BiP to bind to the mu* chains and hence prevent their intracellular transport. The high frequency with which the mu-only surface immunoglobulin positive phenotype is present in our collection of human B-cell lines and the isolation of one of the cell lines from a healthy individual also suggest that B cells of this type may represent a significant subpopulation among the normal human B-cell repertoire.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3122216      PMCID: PMC299720          DOI: 10.1073/pnas.84.24.9199

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

Review 1.  Heavy chain diseases: current findings and concepts.

Authors:  M Seligmann; E Mihaesco; J L Preud'homme; F Danon; J C Brouet
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

2.  Evidence that murine pre-B cells synthesise mu heavy chains but no light chains.

Authors:  P Burrows; M LeJeune; J F Kearney
Journal:  Nature       Date:  1979-08-30       Impact factor: 49.962

3.  The synthesis and processing of the messenger RNAs specifying heavy and light chain immunoglobulins in MPC-11 cells.

Authors:  U Schibler; K B Marcu; R P Perry
Journal:  Cell       Date:  1978-12       Impact factor: 41.582

4.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

5.  Cloning of human immunoglobulin mu gene and comparison with mouse mu gene.

Authors:  N Takahashi; S Nakai; T Honjo
Journal:  Nucleic Acids Res       Date:  1980-12-20       Impact factor: 16.971

6.  Murine heavy chain disease.

Authors:  S L Morrison
Journal:  Eur J Immunol       Date:  1978-03       Impact factor: 5.532

7.  An enzymic method for the trace iodination of immunoglobulins and other proteins.

Authors:  J J Marchalonis
Journal:  Biochem J       Date:  1969-06       Impact factor: 3.857

8.  Mouse pre-B cells synthesize and secrete mu heavy chains but not light chains.

Authors:  D Levitt; M D Cooper
Journal:  Cell       Date:  1980-03       Impact factor: 41.582

9.  Selective suppression of the transcription of ribosomal genes in mouse-human hybrid cells.

Authors:  R P Perry; D E Kelley; U Schibler; K Huebner; C M Croce
Journal:  J Cell Physiol       Date:  1979-03       Impact factor: 6.384

10.  Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein.

Authors:  L Hendershot; D Bole; G Köhler; J F Kearney
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

View more
  8 in total

1.  Reduction of endogenous GRP78 levels improves secretion of a heterologous protein in CHO cells.

Authors:  A J Dorner; M G Krane; R J Kaufman
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

2.  An aberrant splicing using a 3' cryptic splice site within the CH1 exon induces truncated mu-chain production.

Authors:  T Komori; H Sugiyama
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

3.  Analysis in vivo of GRP78-BiP/substrate interactions and their role in induction of the GRP78-BiP gene.

Authors:  D T Ng; S S Watowich; R A Lamb
Journal:  Mol Biol Cell       Date:  1992-02       Impact factor: 4.138

4.  Dual EBNA1 promoter usage by Epstein-Barr virus in human B-cell lines expressing unique intermediate cellular phenotypes.

Authors:  K A Taylor; S Wetzel; D S Lyles; B A Pollok
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

5.  Regulating the retention of T-cell receptor alpha chain variants within the endoplasmic reticulum: Ca(2+)-dependent association with BiP.

Authors:  C K Suzuki; J S Bonifacino; A Y Lin; M M Davis; R D Klausner
Journal:  J Cell Biol       Date:  1991-07       Impact factor: 10.539

6.  Translocation t(14;18) in B cell lymphomas as a cause for defective immunoglobulin production.

Authors:  D de Jong; B M Voetdijk; G J Van Ommen; J C Kluin-Nelemans; G C Beverstock; P M Kluin
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

7.  Clonal diversity in the B cell repertoire of patients with X-linked agammaglobulinemia.

Authors:  R Anker; M E Conley; B A Pollok
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

8.  Immunoglobulin gamma 2b transgenes inhibit heavy chain gene rearrangement, but cannot promote B cell development.

Authors:  P E Roth; L Doglio; J T Manz; J Y Kim; D Lo; U Storb
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.